Pharmacokinetics and pharmacodynamics of itepekimab in adults with moderate‐to‐severe atopic dermatitis: Results from two terminated phase II trials
Clinical and Translational Science · 2024-08 · 17 (8)
DOI: 10.1111/cts.13874 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Clinical and Translational Science, online erschienen am 30.07.2024. Verfasst von Matthew P Kosloski und 15 weiteren Autor:innen. Beteiligte Einrichtung: Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Dermatitis, Atopic, Severity of Illness Index. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Interleukin‐33 (IL‐33) is a proinflammatory alarmin cytokine released by damaged epithelial tissue cells that initiates and amplifies both type 1 and type 2 inflammatory cascades. A role for IL‐33 in atopic dermatitis (AD; a chronic, relapsing type 2 inflammatory disease of the skin) has been proposed. Itepekimab is a novel human IgG4P monoclonal antibody against IL‐33, currently in clinical development for chronic obstructive pulmonary disease (COPD). Two global phase II studies—a dose‐ranging itepekimab monotherapy study (NCT03738423) and a proof‐of‐concept study of itepekimab alone and in combination with dupilumab (NCT03736967)—were conducted in patients with moderate‐to‐severe AD to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy; both studies were terminated following an interim analysis of the proof‐of‐concept study, which failed to demonstrate the efficacy of itepekimab. In these two studies, itepekimab exhibited linear and dose‐proportional pharmacokinetics. Pharmacodynamics of total IL‐33 indicated that itepekimab saturated binding to the target in serum at 300 mg q2w and q4w doses, and decreased blood eosinophil counts. Concentration–time profiles of itepekimab and total IL‐33 were similar for itepekimab with or without dupilumab, and between East Asian and non‐East Asian subgroups. Itepekimab was generally well tolerated, both alone and in combination with dupilumab. The lack of clinical efficacy for itepekimab observed in these studies suggests that IL‐33 may not be a key pathogenic driver in moderate‐to‐severe AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA.
- Icahn School of Medicine at Mount Sinai Medical Center, New York, New York, USA.
- Rockefeller University, New York, New York, USA.
- Sheffield Dermatology Research, University of Sheffield, Sheffield, UK.
- Sheffield Children's Hospital, Sheffield, UK.
- Division of Allergy and Immunology, Department of Dermatology, Venerology and Allergy, Charité-Universitätsmedizin Berlin, Berlin, Germany.
ORCID-Profile: Matthew P Kosloski, Emma Guttman-Yassky, Michael J Cork, Dong-Ho Nahm, Hélène Goulaouic, John D Davis
Zitieren
APA
Kosloski, M. P., Guttman-Yassky, E., Cork, M. J., Worm, M., Nahm, D. H., Zhu, X., Ruddy, M. K., Harel, S., Kamal, M. A., Goulaouic, H., Xu, C. R., Avetisova, E., Davis, J. D., Nivens, M. C., Shabbir, A., & Radin, A. (2024). Pharmacokinetics and pharmacodynamics of itepekimab in adults with moderate‐to‐severe atopic dermatitis: Results from two terminated phase II trials. Clinical and Translational Science, 17(8). https://doi.org/10.1111/cts.13874
Vancouver
Kosloski MP, Guttman-Yassky E, Cork MJ, Worm M, Nahm DH, Zhu X, et al. Pharmacokinetics and pharmacodynamics of itepekimab in adults with moderate‐to‐severe atopic dermatitis: Results from two terminated phase II trials. Clinical and Translational Science. 2024;17(8). doi:10.1111/cts.13874
BibTeX
@article{Kosloski2024,
author = {Kosloski, Matthew P and Guttman-Yassky, Emma and Cork, Michael J and Worm, Margitta and Nahm, Dong-Ho and Zhu, Xiaoping and Ruddy, Marcella K and Harel, Sivan and Kamal, Mohamed A and Goulaouic, Hélène and Xu, Christine R and Avetisova, Elena and Davis, John D and Nivens, Michael C and Shabbir, Arsalan and Radin, Allen},
title = {Pharmacokinetics and pharmacodynamics of itepekimab in adults with moderate‐to‐severe atopic dermatitis: Results from two terminated phase II trials},
journal = {Clinical and Translational Science},
year = {2024},
volume = {17},
number = {8},
doi = {10.1111/cts.13874}
}
EUVIMED